VBLT Vascular Biogenics Ltd. gains 16% Nov 17, 2017

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases in Israel. Its lead product candidates include VB-111, a gene-based biologic that is in III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; in Phase II clinical trials to treat thyroid cancer; and in Phase II clinical trials for the treatment of ovarian cancer. The company's pipeline candidates comprise VB-511, an anti-angiogenic candidate for oncology; and VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Or Yehuda, Israel. http://www.priceseries.com/trade/VBLT-Vascular-Biogenics-Ltd-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2017110220171117.html